Vistagen Therapeutics, Inc. (VTGN)Healthcare | Biotechnology | South San Francisco, United States | NasdaqCM
0.25 USD
0.00
(-0.158%) ⇩
(July 14, 2026, 9:54 a.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 3:32 a.m. EDT
The investment case here is fractured by a brutal multi-year decline. The stock has lost nearly 98% of its value over the last nine years, with the most recent annual performance showing another significant drop. While the company recently reported Phase 3 extension results for its anxiety drug, which has generated headlines, the financial reality is stark: the business is burning cash aggressively with operating margins in the negative 35% range and no free cash flow. The balance sheet, while currently liquid, faces severe execution risks highlighted by recent workforce cuts. The options market reflects this desperation, with traders buying deep out-of-the-money calls hoping for a miracle, but the fundamental trajectory suggests the market has already priced in a failure to deliver sustainable growth. With no dividend to provide income and a history of repeated value traps, this remains a high-risk speculative vehicle rather than a viable investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.121927 |
| AutoARIMA | 0.125333 |
| AutoETS | 0.126695 |
| AutoTheta | 0.128545 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 11% |
| H-stat | 69.32 |
| Ljung-Box p | 0.010 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 8.07 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.939 |
| Revenue per Share | 0.033 |
| Market Cap | 10,352,487 |
| Forward P/E | -0.16 |
| Beta | 0.40 |
| Website | https://www.vistagen.com |
As of July 11, 2026, 3:32 a.m. EDT: Options activity is dominated entirely by out-of-the-money calls, with significant open interest concentrated at strikes of $1.00 and $2.00. This indicates speculative positioning for a massive recovery or a 'lottery ticket' scenario rather than a measured rebound. Conversely, put volume is negligible, suggesting a lack of organized hedging against further downside, though implied volatility remains elevated on the call side reflecting uncertainty.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.8888889 |
| Address1 | 343 Allerton Avenue |
| All Time High | 1,890.0 |
| All Time Low | 0.2 |
| Ask | 0.3242 |
| Ask Size | 2 |
| Average Analyst Rating | 3.0 - Hold |
| Average Daily Volume10 Day | 7,891,150 |
| Average Daily Volume3 Month | 2,143,675 |
| Average Volume | 2,143,675 |
| Average Volume10Days | 7,891,150 |
| Beta | 0.395 |
| Bid | 0.174 |
| Bid Size | 2 |
| Book Value | 0.897 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,798,675,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.2523 |
| Current Ratio | 3.669 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.255 |
| Day Low | 0.246 |
| Debt To Equity | 2.939 |
| Display Name | Vistagen Therapeutics |
| Earnings Call Timestamp End | 1,770,933,600 |
| Earnings Call Timestamp Start | 1,770,933,600 |
| Earnings Timestamp | 1,781,553,600 |
| Earnings Timestamp End | 1,786,046,400 |
| Earnings Timestamp Start | 1,786,046,400 |
| Ebitda | -71,927,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.473 |
| Enterprise To Revenue | -26.785 |
| Enterprise Value | -33,990,100 |
| Eps Current Year | -1.475 |
| Eps Forward | -1.54 |
| Eps Trailing Twelve Months | -1.79 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.5536 |
| Fifty Day Average Change | -0.30130002 |
| Fifty Day Average Change Percent | -0.5442558 |
| Fifty Two Week Change Percent | -88.88889 |
| Fifty Two Week High | 5.14 |
| Fifty Two Week High Change | -4.8877 |
| Fifty Two Week High Change Percent | -0.95091444 |
| Fifty Two Week Low | 0.2 |
| Fifty Two Week Low Change | 0.05229999 |
| Fifty Two Week Low Change Percent | 0.26149994 |
| Fifty Two Week Range | 0.2 - 5.14 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,308,663,000,000 |
| Float Shares | 32,363,937 |
| Forward Eps | -1.54 |
| Forward P E | -0.16383117 |
| Free Cashflow | -40,496,752 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 41 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 1,269,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00285 |
| Held Percent Institutions | 0.40775 |
| Implied Shares Outstanding | 41,032,453 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,774,915,200 |
| Last Split Date | 1,686,096,000 |
| Last Split Factor | 1:30 |
| Long Business Summary | Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California. |
| Long Name | Vistagen Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 10,352,487 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_7691787 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -69,685,000 |
| Next Fiscal Year End | 1,806,451,200 |
| Non Diluted Market Cap | 10,368,900 |
| Number Of Analyst Opinions | 2 |
| Open | 0.246 |
| Operating Cashflow | -66,436,000 |
| Operating Margins | -35.95054 |
| Payout Ratio | 0.0 |
| Phone | 650 577 3600 |
| Previous Close | 0.2527 |
| Price Eps Current Year | -0.17105085 |
| Price Hint | 4 |
| Price To Book | 0.2812709 |
| Price To Sales Trailing12 Months | 8.157989 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.548 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.0 |
| Region | US |
| Regular Market Change | -0.00040000677 |
| Regular Market Change Percent | -0.15829314 |
| Regular Market Day High | 0.255 |
| Regular Market Day Low | 0.246 |
| Regular Market Day Range | 0.246 - 0.255 |
| Regular Market Open | 0.246 |
| Regular Market Previous Close | 0.2527 |
| Regular Market Price | 0.2523 |
| Regular Market Time | 1,784,037,271 |
| Regular Market Volume | 227,722 |
| Return On Assets | -0.67836 |
| Return On Equity | -1.31593 |
| Revenue Per Share | 0.033 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 41,032,453 |
| Shares Percent Shares Out | 0.0388 |
| Shares Short | 1,591,673 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 2,020,399 |
| Short Name | VistaGen Therapeutics, Inc. |
| Short Percent Of Float | 0.038900003 |
| Short Ratio | 0.5 |
| Source Interval | 15 |
| State | CA |
| Symbol | VTGN |
| Target High Price | 1.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 1.0 |
| Target Median Price | 1.0 |
| Total Cash | 45,403,000 |
| Total Cash Per Share | 1.107 |
| Total Debt | 1,044,000 |
| Total Revenue | 1,269,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.79 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.62565 |
| Two Hundred Day Average Change | -1.37335 |
| Two Hundred Day Average Change Percent | -0.84480053 |
| Type Disp | Equity |
| Volume | 227,722 |
| Website | https://www.vistagen.com |
| Zip | 94,080 |